<2>Treatment with GLP-1 drugs must not replace obesity prevention in low and middle income countries
<3>The World Health Organization’s New Guidelines on GLP-1 Receptor Agonists
The World Obesity Federation has welcomed the World Health Organization’s first guideline Guidelines on the pharmacological treatment of obesity recommending glucagon-like peptide-1 (GLP-1) receptor agonists as a milestone for obesity care. The federation emphasises that medical treatment should be delivered as part of comprehensive, long term obesity management rather than as a standalone solution. Research suggests that GLP-1 receptor agonists can be effective in reducing body weight and improving glycemic control in patients with type 2 diabetes. However, the federation also highlights the need for a multifaceted approach to obesity prevention and management, which includes lifestyle interventions, education, and policy changes.
<3>Challenges in Low and Middle Income Countries
For low and middle income